Cabbacis Inc Stock Price, News & Analysis

Cabbacis (OTCQB: CABI) has been granted U.S. Patent No. 12,349,724 for vaporizer pods, expanding its intellectual property portfolio to 31 countries. The patent, valid until July 2038, covers pods containing blends of conventional or reduced-nicotine reconstituted tobacco with hemp for oral electronic vaporizers.

The company's iBlend™ product line features reduced-nicotine vaporizer pods and cigarettes containing 95% less nicotine than conventional brands. These products are designed to help users transition to less harmful tobacco alternatives. The patent portfolio now includes protection in major markets including the United States, China, Europe, Brazil, and Japan.

Cabbacis (OTCQB: CABI) has announced positive clinical trial results for its iBlend™ cigarettes, demonstrating significant efficacy in reducing cravings for regular cigarettes. The trial, conducted by Rose Research Center, tested four types of reduced-nicotine cigarettes on 16 smokers, including three variants with different hemp concentrations (5%, 10%, and 20%) and one without hemp.

Key findings revealed that all iBlend™ variants achieved higher satisfaction ratings on the standardized mCEQ questionnaire compared to other 95% reduced-nicotine cigarettes. Notably, the 20% hemp variant showed statistically significant reduction in exhaled carbon monoxide levels. The study supports Cabbacis's strategy to develop FDA-compliant products ahead of potential regulations requiring ~95% nicotine reduction in U.S. cigarettes.

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer, has received SEC qualification for a Regulation A (Tier 2) offering on June 3rd, 2025. The company aims to raise up to $7 million through the public sale of common stock priced at $2.00 per share. The offering is accessible to both accredited and non-accredited investors, with the latter subject to Regulation A investment limits. Proceeds will fund product development and commercialization, including FDA premarket tobacco product applications, tobacco and hemp plantings, general corporate purposes, and potential acquisitions. The offering documents are available on the company's website.

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco manufacturer, has filed its Annual Report for fiscal year 2024. The company, focused on developing harm-reduction products under the iBlend™ brand, reported increased losses with:

• Net loss from operations of $956,464 in 2024 (vs $380,174 in 2023)
• Total net loss of $915,886 in 2024 (vs $379,068 in 2023)
• Negative EPS of $0.15 (vs -$0.07 in 2023)

As a development-stage company, CABI generated no revenue in 2024. The company reports significant progress in product development, including their ongoing clinical trial of iBlend™ reduced-nicotine cigarettes, which is over 50% complete.

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company, has received DTC Eligibility approval from the Depository Trust Company. This development follows the company's previous listing approval on the OTCQB under the symbol 'CABI'.

DTC, a subsidiary of the Depository Trust and Clearing (DTCC), manages electronic clearing and settlement of publicly traded companies' shares. The DTC Eligibility status enables electronic clearing and settlement of Cabbacis shares, expediting stock and cash receipt processes while simplifying trading and share transfers between brokerage companies.

Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company, has received approval for listing its common stock on the OTCQB Venture Market. The OTCQB, operated by OTC Markets Group, serves entrepreneurial and development stage companies among its 12,000+ securities. The company expects this listing to enhance shareholder liquidity, transparency, and expand its investor reach.